foy 251 has been researched along with camostat in 8 studies
| Studies (foy 251) | Trials (foy 251) | Recent Studies (post-2010) (foy 251) | Studies (camostat) | Trials (camostat) | Recent Studies (post-2010) (camostat) |
|---|---|---|---|---|---|
| 9 | 0 | 2 | 337 | 14 | 93 |
| Protein | Taxonomy | foy 251 (IC50) | camostat (IC50) |
|---|---|---|---|
| Transmembrane protease serine 2 | Homo sapiens (human) | 0.018 | |
| Prothrombin | Homo sapiens (human) | 0.399 | |
| Serine protease hepsin | Homo sapiens (human) | 0.0235 | |
| Trypsin-1 | Homo sapiens (human) | 0.0035 | |
| Trypsin-2 | Homo sapiens (human) | 0.0035 | |
| Procathepsin L | Homo sapiens (human) | 0.018 | |
| Furin | Homo sapiens (human) | 0.018 | |
| Trypsin-3 | Homo sapiens (human) | 0.0035 | |
| Transmembrane protease serine 6 | Homo sapiens (human) | 0.018 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, H; Kamiyasu, K; Kato, M; Maruyama, T; Miyazaki, T; Nakai, H; Nakayama, Y; Odagaki, Y; Sakaki, K; Senokuchi, K | 1 |
| Fuji, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S | 1 |
| Arnold, R; Beckh, K; Göke, B; Müller, R | 1 |
| Yonezawa, H | 1 |
| Bonn, R; Brindley, CJ; Chasseaud, LF; Cheng, KN; Hood, AJ; Irons, SR; Midgley, I; Proctor, P | 1 |
| Adachi, M; Kakizoe, Y; Kitamura, K; Ko, T; Maekawa, A; Miyoshi, T; Shiraishi, N; Tomita, K; Wakida, N | 1 |
| Chen, J; Guo, H; Huang, Y; Liu, C; Shan, W; Xiao, Z | 1 |
| Bajraktari-Sylejmani, G; Haefeli, WE; Weiss, J | 1 |
8 other study(ies) available for foy 251 and camostat
| Article | Year |
|---|---|
New orally active serine protease inhibitors.
Topics: Administration, Oral; Amino Acid Sequence; Animals; Benzamidines; Dogs; Molecular Sequence Data; Rats; Serine Proteinase Inhibitors | 1995 |
Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Esters; Gabexate; Guanidines; Male; Organ Size; Pancreas; Pancreatitis; Proglumide; Rats; Rats, Inbred Strains; Secretin; Trypsin Inhibitors | 1990 |
Elimination of the low-molecular weight proteinase inhibitor camostate (FOY 305) and its degradation products by the rat liver.
Topics: Administration, Oral; Animals; Benzoates; Biotransformation; Esters; Female; Gabexate; Guanidines; In Vitro Techniques; Liver; Perfusion; Protease Inhibitors; Rats; Rats, Inbred Strains | 1987 |
Discrepancy between the potency of various trypsin inhibitors to inhibit trypsin activity and the potency to release biologically active cholecystokinin-pancreozymin.
Topics: Animals; Benzamidines; Cholecystokinin; Duodenum; Esters; Gabexate; Guanidines; Male; Pancreas; Rats; Rats, Inbred Strains; Stimulation, Chemical; Trypsin Inhibitors | 1984 |
Metabolic fate of 14C-camostat mesylate in man, rat and dog after intravenous administration.
Topics: Adult; Animals; Benzoates; Biotransformation; Blood Proteins; Carbon Radioisotopes; Dogs; Esters; Gabexate; Guanidines; Humans; Infusions, Intravenous; Male; Protease Inhibitors; Protein Binding; Rats; Rats, Sprague-Dawley; Tissue Distribution; Trypsin Inhibitors | 1994 |
Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Cells, Cultured; Esters; Gabexate; Guanidines; Hypertension; Kidney; Mice; Rats; Rats, Inbred Dahl; RNA, Small Interfering; Serine Endopeptidases; Serine Proteinase Inhibitors | 2009 |
Enhanced stability of oral insulin in targeted peptide ligand trimethyl chitosan nanoparticles against trypsin.
Topics: Administration, Oral; Chitosan; Drug Carriers; Drug Delivery Systems; Endocytosis; Esters; Gabexate; Guanidines; Insulin; Intestinal Mucosa; Ligands; Nanoparticles; Polyglutamic Acid; Trypsin; Trypsin Inhibitors | 2015 |
Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line; Cell Survival; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP3A; Drug Interactions; Esters; Guanidines; Humans; Organic Anion Transporters; Pregnane X Receptor; Receptors, Aryl Hydrocarbon; RNA, Messenger; Serine Endopeptidases; Serine Proteinase Inhibitors | 2021 |